Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Sargramostim in CLL
NCT00265915Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2005
- Primary completion
- Mar 2006
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 2 trial of rituximab, sargramostim in chronic lymphocytic leukemia (CLL), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jul 2005; status: terminated.
02
Drugs
rituximabsargramostim
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00265915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00265915.